國家衛生研究院 NHRI:Item 3990099045/13754
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 913465      線上人數 : 1135
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/13754


    題名: The effects of heterologous immunization with prime‐boost covid‐19 vaccination against sars‐cov‐2
    作者: Ho, TC;Chen, YMA;Chan, HP;Chang, CC;Chuang, KP;Lee, CH;Yuan, CH;Tyan, YC;Yang, MH
    貢獻者: National Institute of Infectious Diseases and Vaccinology
    摘要: Coronavirus Disease 2019 (COVID‐19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has become the global challenge. Reaching global herd immunity will help end the COVID‐19 pandemic. However, vaccine shortage and vaccine hesitancy are the obstacles to achieve global herd immunity against SARS‐CoV‐2. The current homologous vaccine regimen is experimentally switching to heterologous vaccination at several study sites. However, the reactogenicity of heterologous ChAdOx1‐S and mRNA vaccination against SARS‐CoV‐2 is still unclear. We have conducted a systematic review to summarize the current findings on the safety and immunogenicity of this heterologous vaccination and elucidate their implications against SARS‐CoV‐2. This systematic review was conducted by the guidelines of PRISMA. Articles were searched from PubMed and other sources (MedRixv and Google scholar) starting from 1 January to 5 September 2021. The search term was heterologous ChAdOx1‐S and BNT162b2 or mRNA‐1273 vaccination. Our review found that participants with ChA-dOx1/BNT162b2, ChAdOx1‐S/mRNA‐1273 or BNT162b2/ChAdOx1‐S did not have the serious ad-verse events seen with homologous vaccination. Participants with the heterologous regimen (ChA-dOx1/BNT162b2, ChAdOx1‐S/mRNA‐1273 or BNT162b2/ChAdOx1‐S), compared with those with two doses of ChAdOx1‐S, have shown a more robust immune responses against SARS‐CoV‐2, such as higher levels of responsive antibodies or increased numbers of spike‐specific T‐cells. Neverthe-less, these immune responses were slightly diminished in the recipients of BNT162b2/ChAdOx1‐S. Also, the safety study of heterologous ChAdOx1‐S/mRNA vaccination was based on small popula-tions. Further studies to enclose diverse categories, such as race/ethnicity or geography, may be necessary. Overall, the heterologous immunization with ChAdOX1‐S and the mRNA vaccine may improve the vaccine shortage related slow pace of reaching herd immunity, especially using the heterologous immunization with ChAdOx1‐S/BNT162b2.
    日期: 2021-10-11
    關聯: Vaccines. 2021 Oct 11;9(10):Article number 1163.
    Link to: http://dx.doi.org/10.3390/vaccines9101163
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2076-393X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000835558000001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85117515412
    顯示於類別:[其他] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    SCP85117515412.pdf445KbAdobe PDF187檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋